Clinical Trials Logo

Clinical Trial Summary

Study Object: Stage III lung cancer with epidermal growth factor receptor (EGFR) sensitive mutation. Study Method: The study subjects will be randomly assigned to the intervention group and the control group. The intervention group will receive radiotherapy combined with erlotinib treatment, while the control group will receive concurrent radiotherapy combined with chemotherapy. The differences in short-term efficacy, long-term efficacy, and incidence of adverse reactions between the two groups will be observed. Observation Indicators: Short-term efficacy indicators: Complete remission (CR) rate, partial remission (PR) rate, and objective response rate (ORR). Long-term efficacy indicators: Overall survival (OS) and progression-free survival (PFS). Adverse reaction indicators: Incidence of lung toxicity, hematological toxicity, and gastrointestinal reactions.


Clinical Trial Description

The following tasks need to be completed at the time of enrollment: screening, signing the informed consent form, random assignment according to the randomization table, detailed patient medical history, physical examination, and collection of baseline chest-enhanced CT as imaging data before treatment. All eligible patients who meet the baseline inclusion criteria will be enrolled using an online central randomization system, with the following stratification factors: disease staging at the beginning of the study treatment (ⅢA vs ⅢB vs ⅢC), histology (adenocarcinoma vs. others), and EGFR mutation status (exon 19 vs. exon 21). Patients will be randomly assigned in a 1:1 ratio. In the intervention group,Radiotherapy was administered using Intensity-Modulated Radiation Therapy (IMRT) technique, with a prescribed dose of 60 Gy in 30 fractions. Ametinib was orally administered at 110 mg per day, starting from the first day of radiotherapy and continued for 42 days until the completion of radiotherapy, followed by continuous medication until disease progression. In the control group,Radiotherapy was administered using Intensity-Modulated Radiation Therapy (IMRT) technique, with a prescribed dose of 60 Gy in 30 fractions. Chemotherapy with paclitaxel at 135 mg/m2 and cisplatin at 70 mg/m2 was intravenously infused for two cycles during the 1st and 4th weeks. After the completion of radiotherapy, there was a rest period of 4 weeks, followed by continuation of the TP regimen for consolidation chemotherapy for 4 cycles. Follow-up will take place from August 30, 2023, to December 30, 2025, based on the time of death. Chest and upper abdominal enhanced CT, cervical supraclavicular lymph node color Doppler ultrasound, head MRI, whole-body bone scan, and other examinations will be performed at treatment completion, 1 month after treatment completion, 3 months after treatment completion, every 3 months within 2 years, and every 6 months in the 3rd year for efficacy and survival evaluation. Statistical Analysis: ① Stratified (based on disease stage at the beginning of the study treatment, histology, and EGFR mutation status) and unstratified log-rank tests will be used to compare Progression-Free Survival (PFS) and Overall Survival (OS) at a two-sided significance level of 0.05. The median PFS and corresponding 95% confidence intervals (CI) for both groups will be calculated. ② Cox proportional hazards models will be used to estimate Hazard Ratios (HRs) and 95% CI for PFS and OS. PFS and OS curves will be estimated using the Kaplan-Meier method. ③ Fisher's exact test will be used to compare the difference in Objective Response Rate (ORR) between the two groups. The difference in ORR and its 95% CI will be presented together using the normal approximation method. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05994339
Study type Interventional
Source Laibin People's Hospital
Contact
Status Not yet recruiting
Phase Phase 2/Phase 3
Start date September 1, 2023
Completion date December 8, 2025

See also
  Status Clinical Trial Phase
Recruiting NCT06003075 - Induction Chemo-Nivo in Unresectable Stage III NSCLC Phase 2
Enrolling by invitation NCT04305613 - Cardiotoxicity in Locally Advanced Lung Cancer Patients Treated With Chemoradiation Therapy
Not yet recruiting NCT06060964 - Enabling Remote Access to Breathe Easier: A Novel Approach to Improve Symptom Management Early Phase 1
Recruiting NCT04991025 - Adding Certolizumab to Chemotherapy + Nivolumab in People Who Have Lung Cancer That Can Be Treated With Surgery Phase 2
Recruiting NCT06111807 - Clinical Validation and Benchmarking of Top Performing ctDNA Diagnostics - Stage III NSCLC
Completed NCT04825912 - Resilience Measurement in Older Adults With Late-Stage Lung Cancer N/A
Active, not recruiting NCT03141359 - Use of High Dose Radiation Followed by Chemotherapy and Radiation to Treat Locally Advanced NSCLC Phase 2
Recruiting NCT06086574 - Developing Circulating and Imaging Biomarkers Towards Personalised Radiotherapy in Lung Cancer
Recruiting NCT03872661 - Neoadjuvant IBI308, Bevacizumab, Plus Pemetrexed and Carboplatin Followed by Surgery in Unresectable Stage III NSCLC Phase 2
Not yet recruiting NCT05358691 - A Trial of AN0025 With Chemoradiation Therapy in Stage III NSCLC Participants Phase 1
Recruiting NCT06432972 - Accelerated Pulmonary Rehabilitation in the Preoperative Period N/A
Active, not recruiting NCT04364776 - Radiomic Signature as Predictive Marker of Response to Chemoradiation and Durvalumab in Stage III NSCLC.
Recruiting NCT05258448 - COr Loco-regional Advanced Lung Cancer Treated With Chemo-radiotherapy (COLA)
Recruiting NCT05996263 - Prognostic Value of Combined Approach Based on KEAP1/NFE2L2 Mutations and Pre-therapeutic FDG-PET/CT Radiomic Analysis in Advanced Non-small-cell Lung Cancer PDL1 ≥ 50% Treated With Pembrolizumab (PEMBROMIC)
Active, not recruiting NCT04003246 - Phase II Concurrent Durvalumab and Radiotherapy for for Stage III Non-Small Cell Lung Cancer Phase 2
Completed NCT04057196 - Self-System Therapy for Older Adults With Lung Cancer N/A